Zogenix Seeks FDA Expanded OK of Fintepla in Lennox-Gastaut Syndrome
28 Septembre 2021 - 3:18PM
Dow Jones News
By Colin Kellaher
Zogenix Inc. on Tuesday said it filed with the U.S. Food and
Drug Administration for expanded approval of Fintepla for the
treatment of seizures associated with Lennox-Gastaut syndrome.
The Emeryville, Calif., pharmaceutical company said the filing
is supported by data from a Phase 3 study that showed Fintepla was
superior to placebo in reducing the frequency of drop seizures in
patients with the severe, rare form of epilepsy that isn't
well-controlled by currently available anti-seizure
medications.
The FDA last year approved Fintepla for the treatment of
seizures associated with Dravet syndrome, a rare childhood-onset
epilepsy, in patients two years of age and older.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 28, 2021 09:03 ET (13:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Zogenix (NASDAQ:ZGNX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Zogenix (NASDAQ:ZGNX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Zogenix Inc (NASDAQ): 0 recent articles
Plus d'articles sur Zogenix Inc